Open main menu

Psychiatrienet β

Fluvoxamine-agomelatine

Revision as of 11:29, 5 March 2010 by Musys (talk | contribs) (geen newline/spaties voor ref)
Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from fluvoxamine to agomelatine.[1] [2]

Nietinrijdenbord.png Stop fluvoxamine
  • Before day 1: gradually reduce dosage of fluvoxamine to a maximum of 50 mg/day, when this dosage is > 50 mg/day.
  • Day 1: reduce dosage of fluvoxamine further to 25 mg/day.
  • Day 8: stop administration of fluvoxamine.
Eenrichtingbord.png Start agomelatine
  • Day 8-14: a wash-out period of one week is necessary.
  • Day 15: start administration of agomelatine after this period in a dosage of 25 mg/day.
  • If necessary, the dosage of agomelatine can be increased to 50 mg/day.
Infobord.png More information
  • Fluvoxamine stops the metabolism of agomelatine via CYP1A2 (90%) and via CYP2C9/2C19 (10%).[3]
  1. ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. ↑ McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Retrieved from "https://wiki.psychiatrienet.nl/w/index.php?title=Fluvoxamine-agomelatine&oldid=4715"